PT - JOURNAL ARTICLE AU - Marques, Patricia X. AU - Wand, Handan AU - Nandy, Melissa AU - Tan, Chun AU - Shou, Huizhong AU - Terplan, Mishka AU - Mark, Katrina AU - Brotman, Rebecca M. AU - Wilson, David P. AU - Ravel, Jacques AU - Hsia, Ru-ching AU - M. Bavoil, Patrik TI - Serum antibodies to surface proteins of <em>Chlamydia trachomatis</em> as candidate biomarkers of disease: Results from the Baltimore Chlamydia Adolescent/Young Adult Reproductive Management (CHARM) cohort AID - 10.1101/2021.05.25.21257614 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.25.21257614 4099 - http://medrxiv.org/content/early/2021/05/27/2021.05.25.21257614.short 4100 - http://medrxiv.org/content/early/2021/05/27/2021.05.25.21257614.full AB - Background We previously observed that the nine-member family of autotransported polymorphic membrane proteins (Pmps) of Chlamydia trachomatis is variably expressed in cell culture. Additionally, C. trachomatis-infected patients display variable Pmp-specific serum antibody profiles indirectly suggesting expression of unique Pmp profiles is an adaptive response to host-specific stimuli during infection. Here, we propose that the host response to Pmps and other outer surface proteins may correlate with disease severity.Methods This study tests this hypothesis using an ELISA that measures serum IgG antibodies specific for the nine C. trachomatis Pmp subtypes and four immunodominant antigens (MOMP, OmcB, GroEL, ClpP) in 265 participants of the Chlamydia Adolescent/Young Adult Reproductive Management (CHARM) cohort.Results More C. trachomatis-infected females displayed high Pmp-specific antibody levels (cut-off Indexes) than males (35.9-40.7% of females vs. 24.2-30.0% of males), with statistical significance for PmpC, F and H (P&lt;0.05). Differences in Pmp-specific antibody profiles were not observed between C. trachomatis-infected females with a clinical diagnosis of pelvic inflammatory disease (PID) and those without. However, a statistically significant association between high levels of OmcB-specific antibody and a PID diagnosis (P&lt;0.05) was observed.Conclusions Using antibody levels as an indirect measure of antigen expression, our results suggest that gender- and/or site-specific (cervix in females vs. urethra in males) stimuli control pmp expression in infected patients. They also support the possible existence of immune biomarkers of chlamydial infection associated with disease and underline the need for high resolution screening in human serum.Competing Interest StatementThe authors have declared no competing interest.Funding StatementResearch reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number U19AI084044. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. No other services or payment were received from a third party by any of the authors or their institutions Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:CHARM (HP-00042320) was reviewed and approved by the Institutional Review Board of the University of Maryland Baltimore. The CHARM study details are described in reference 20: Mark KS, Brotman RM, Martinez-Greiwe S, Terplan M, Bavoil P, Ravel J. Chlamydia in adolescent/adult reproductive management trial study (CHARM): Clinical core protocol. Contemp Clin Trials Commun. 2019;16:100414All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data provided in the manuscript are available upon request.